



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington D U 20231 www.uspto.gov

DATE MAILED: 01/28/2002

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/424,458	03/16/2000	NICHOLAS HAYWARD	13198	8014
75	01/28/2002			
SCULLY SCOTT MURPHY & PRESSER			EXAMINER	
400 GARDEN GARDEN CITY			LEFFERS JR, GERALD G	
			ART UNIT	PAPER NUMBER
			1636	

Please find below and/or attached an Office communication concerning this application or proceeding.

•		Application No.	Applicant(s)
Office Action Summary		09/424,458	HAYWARD ET AL.
		Examiner	Art Unit
Th	MAU INO DATE	Gerald Leffers	1636
Period for Re	e MAILING DATE of this communication app ply	ears on the cover sheet with the c	orrespondenc address
- Extensions of after SIX (6) - If the period - If NO period - Failure to re - Any reply recearned pater	ENED STATUTORY PERIOD FOR REPLY ING DATE OF THIS COMMUNICATION. of time may be available under the provisions of 37 CFR 1.13 MONTHS from the mailing date of this communication. for reply specified above is less than thirty (30) days, a reply for reply is specified above, the maximum statutory period we ply within the set or extended period for reply will, by statute, believed by the Office later than three months after the mailing on term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from the statutory minimum of thirty (30).	. ely filed will be considered timely. he mailing date of this communication
Status			
1) Res	sponsive to communication(s) filed on	_ ·	
		s action is non-final.	
3) Sind	ce this application is in condition for allowar sed in accordance with the practice under E	nce except for formal matters, pro Ex parte Quayle, 1935 C.D. 11, 48	osecution as to the merits is 53 O.G. 213.
Disposition of			
4)⊠ Clain	n(s) <u>1-24</u> is/are pending in the application.		
4a) O	f the above claim(s) is/are withdraw	n from consideration.	
	n(s) is/are allowed.		
6)☐ Claim	n(s) is/are rejected.		
7)☐ Claim	n(s) is/are objected to.		
8)⊠ Claim	n(s) <u>1-24</u> are subject to restriction and/or ele	ection requirement.	
Application Pa		·	
9)∏ The sr	pecification is objected to by the Examiner.		
	rawing(s) filed on is/are: a)□ accepte	ed or b) objected to by the Exam	iner
Appi	icant may not request that any objection to the o	drawing(s) be held in abeyance. See	37 CFR 1 85(a)
11) <u></u> The pr	oposed drawing correction filed on i	s: a)	ed by the Examiner.
lf apı	proved, corrected drawings are required in reply	to this Office action.	•
12) <u></u> The oa	ath or declaration is objected to by the Exar	miner.	
Priority under	35 U.S.C. §§ 119 and 120		
13) Ackno	owledgment is made of a claim for foreign p	oriority under 35 U.S.C. § 119(a)-	(d) or (f).
	b) Some * c) None of:		. , . ,
1.	Certified copies of the priority documents h	nave been received.	
2.	Certified copies of the priority documents h	nave been received in Application	No
3.	Copies of the certified copies of the priority application from the International Burea attached detailed Office action for a list of	documents have been received	in this National Stage
14) Acknow	ledgment is made of a claim for domestic p	priority under 35 U.S.C. § 119(e)	(to a provisional application)
a) ∐ Th 15)∏ Acknow Attachment(s)	ne translation of the foreign language provisurely relation of the foreign language provision for domestic process.	sional application has been received	ved.
<ol><li>Notice of Draft</li></ol>	erences Cited (PTO-892) tsperson's Patent Drawing Review (PTO-948) sclosure Statement(s) (PTO-1449) Paper No(s)	5)   Notice of Informal Pate	TO-413) Paper No(s)
TO-326 (Rev. 04-01)	Office Action	n Summary	Part of Paper No. 10

Application/Control Number: 09/424,458

Art Unit: 1636

## DETAILED ACTION

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions that are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-3, 8-10, 15-16, drawn to an isolated nucleic acid encoding a regulator of gene expression, MCG4 (SEQ ID NOS: 2-3), and to a method of detecting a condition caused by an aberration in *mcg4* due to nucleotide alterations in the coding sequence.

Group II, claim(s) 1-2, 4-5, 8, 11-12, 15 and 19, drawn to an isolated nucleic acid encoding a regulator of gene expression, MCG7 (SEQ ID NOS: 4-5), and to a method of detecting a condition caused by an aberration in *mcg7* due to nucleotide alterations in the coding sequence.

Group III, claim(s) 1-2, 4-5, 8, 11-12, 15 and 19, drawn to an isolated nucleic acid encoding a regulator of gene expression, MCG7 (SEQ ID NOS: 6-7), and to a method of detecting a condition caused by an aberration in *mcg7* due to nucleotide alterations in the coding sequence.

Group IV, claim(s) 1-2, 6-8, 13-15 and 22, drawn to an isolated nucleic acid encoding a regulator of gene expression, MCG18 (SEQ ID NOS: 8-9), and to a method of detecting a condition caused by an aberration in *mcg18* due to nucleotide alterations in the coding sequence.

Group V, claim(s) 17, drawn to a method of detecting a condition associated with an aberration in *mcg4* wherein a change in the amino acid sequence of MCG4 is detected (SEQ ID NO: 3).

Group VI, claim(s) 18, drawn to a method of detecting MCG4 with an antibody directed against the protein (SEQ ID NO: 3).

Group VII, claim(s) 20, drawn to a method of detecting a condition associated with an aberration in *mcg7* wherein a change in the amino acid sequence of MCG7 is detected (SEQ ID NO: 5).

Application/Control Number: 09/424,458

Art Unit: 1636

Group VIII, claim(s) 21, drawn to a method of detecting MCG7 with an antibody directed against the protein (SEQ ID NO: 5).

Group IX, claim(s) 20, drawn to a method of detecting a condition associated with an aberration in *mcg7* wherein a change in the amino acid sequence of MCG7 is detected (SEQ ID NO: 7).

Group X, claim(s) 21, drawn to a method of detecting MCG7 with an antibody directed against the protein (SEQ ID NO: 7).

Group XI, claim(s) 23, drawn to a method of detecting a condition associated with an aberration in *mcg18* wherein a change in the amino acid sequence of MCG18 is detected (SEQ ID NO: 9).

Group XII, claim(s) 24, drawn to drawn to a method of detecting MCG18 with an antibody directed against the protein (SEQ ID NO: 9).

The inventions listed as Groups I-XII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of each group is the structural, functional characteristics of the specific nucleic acid or polypeptide featured in that group. For example, the special technical feature for each of Groups I-IV is based upon the particular nucleic acid sequence that encodes a specified regulator of gene expression. The special technical feature of each of Groups V, VII, IX and XI is based upon the particular amino acid sequence for a specified regulator of gene expression that is to be detected. The special technical feature for each of Groups VI, VIII, X and XII is based upon an antibody that specifically recognizes a given regulator of gene expression.

A telephone call was made to Frank Digiglio on 1-8-02 to request an oral election to the above restriction requirement, but did not result in an election being made.

Application/Control Number: 09/424,458

Art Unit: 1636

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G Leffers Jr. whose telephone number is (703) 308-6232. The examiner can normally be reached on 9:30am-6:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached on (703) 305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-7939 for regular communications and (703) 305-7939 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Gerald G Leffers Jr. Examiner Art Unit 1636

*₩* ggl

January 8, 2002

DAVID GUZO

RIMARY EXAMINED